How does dyslipidemia risk compare with respect to FGA potency?

• A. Low-potency FGAs have lower risk, high-potency higher risk
• B. Dyslipidemia risk is identical across potencies
• C. High-potency FGAs have lower dyslipidemia risk
• D. Dyslipidemia is not associated with FGAs

Answer: (A)

The key idea here is that the metabolic side effects linked to first-generation antipsychotics (FGAs) are described in this material as relating to potency. The pattern presented is that higher-potency FGAs have a greater impact on lipid metabolism, leading to a higher risk of dyslipidemia, while lower-potency FGAs carry a lower risk. This reflects the notion that stronger dopamine D2 blockade and broader receptor effects seen with high-potency agents can influence energy balance and lipid pathways more than those seen with low-potency drugs. In this context, the statement that low-potency FGAs have lower risk and high-potency FGAs have higher risk best fits the provided answer. It’s also useful to keep in mind that overall metabolic risk is much more prominent with second-generation antipsychotics, and among FGAs the differences are less consistent across individual drugs in broader literature.